Morepen Labs Stock Surges 15% on ₹825 Crore CDMO Agreement
Loading more articles...
Morepen Labs Soars 15% on ₹825 Crore CDMO Deal Boost
M
Moneycontrol•23-02-2026, 16:30
Morepen Labs Soars 15% on ₹825 Crore CDMO Deal Boost
•Morepen Laboratories shares surged up to 19% intraday, closing over 15% higher on February 23.
•The company secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate worth approximately ₹825 crore from a major global pharmaceutical company.
•Supplies under the agreement are expected to begin in 4-5 months, with execution slated for Q1 of the next financial year.
•Chairman and MD Sushil Suri highlighted the deal as a significant milestone, reflecting global customer trust in Morepen's capabilities.
•Morepen Labs, a vertically integrated pharma company, has seen its stock rise over 30% in one month, with a market cap exceeding ₹2400 crore.